GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00160555 | Liver | NAFLD | Wnt signaling pathway | 74/1882 | 444/18723 | 8.98e-06 | 2.96e-04 | 74 |
GO:01987385 | Liver | NAFLD | cell-cell signaling by wnt | 74/1882 | 446/18723 | 1.05e-05 | 3.33e-04 | 74 |
GO:00301115 | Liver | NAFLD | regulation of Wnt signaling pathway | 57/1882 | 328/18723 | 2.79e-05 | 7.46e-04 | 57 |
GO:00608285 | Liver | NAFLD | regulation of canonical Wnt signaling pathway | 44/1882 | 253/18723 | 2.14e-04 | 3.68e-03 | 44 |
GO:00600705 | Liver | NAFLD | canonical Wnt signaling pathway | 50/1882 | 303/18723 | 3.08e-04 | 4.83e-03 | 50 |
GO:00301774 | Liver | NAFLD | positive regulation of Wnt signaling pathway | 27/1882 | 140/18723 | 6.82e-04 | 8.76e-03 | 27 |
GO:00902634 | Liver | NAFLD | positive regulation of canonical Wnt signaling pathway | 21/1882 | 106/18723 | 1.81e-03 | 1.86e-02 | 21 |
GO:00307055 | Liver | NAFLD | cytoskeleton-dependent intracellular transport | 33/1882 | 195/18723 | 1.98e-03 | 1.98e-02 | 33 |
GO:00323866 | Liver | NAFLD | regulation of intracellular transport | 49/1882 | 337/18723 | 5.34e-03 | 4.11e-02 | 49 |
GO:00109703 | Liver | NAFLD | transport along microtubule | 26/1882 | 155/18723 | 6.30e-03 | 4.69e-02 | 26 |
GO:003238621 | Liver | HCC | regulation of intracellular transport | 231/7958 | 337/18723 | 1.99e-22 | 3.40e-20 | 231 |
GO:019873821 | Liver | HCC | cell-cell signaling by wnt | 247/7958 | 446/18723 | 2.11e-08 | 4.96e-07 | 247 |
GO:001605521 | Liver | HCC | Wnt signaling pathway | 245/7958 | 444/18723 | 3.68e-08 | 8.09e-07 | 245 |
GO:00315031 | Liver | HCC | protein-containing complex localization | 129/7958 | 220/18723 | 9.38e-07 | 1.42e-05 | 129 |
GO:003011121 | Liver | HCC | regulation of Wnt signaling pathway | 180/7958 | 328/18723 | 3.62e-06 | 4.72e-05 | 180 |
GO:003070521 | Liver | HCC | cytoskeleton-dependent intracellular transport | 111/7958 | 195/18723 | 3.25e-05 | 3.28e-04 | 111 |
GO:00109702 | Liver | HCC | transport along microtubule | 90/7958 | 155/18723 | 6.49e-05 | 5.92e-04 | 90 |
GO:006007021 | Liver | HCC | canonical Wnt signaling pathway | 162/7958 | 303/18723 | 7.00e-05 | 6.32e-04 | 162 |
GO:006082821 | Liver | HCC | regulation of canonical Wnt signaling pathway | 137/7958 | 253/18723 | 1.15e-04 | 9.70e-04 | 137 |
GO:003017721 | Liver | HCC | positive regulation of Wnt signaling pathway | 81/7958 | 140/18723 | 1.73e-04 | 1.36e-03 | 81 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
TTC21B | SNV | Missense_Mutation | novel | c.1169N>G | p.Ser390Cys | p.S390C | Q7Z4L5 | protein_coding | deleterious(0.01) | possibly_damaging(0.838) | TCGA-A2-A0CL-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cytoxan | SD |
TTC21B | SNV | Missense_Mutation | rs747866883 | c.902G>A | p.Arg301His | p.R301H | Q7Z4L5 | protein_coding | deleterious(0.04) | probably_damaging(0.999) | TCGA-A8-A0A4-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | tamoxiphen | CR |
TTC21B | SNV | Missense_Mutation | novel | c.3877N>T | p.Leu1293Phe | p.L1293F | Q7Z4L5 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-AC-A5XS-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | femara | SD |
TTC21B | SNV | Missense_Mutation | novel | c.3799N>A | p.Ala1267Thr | p.A1267T | Q7Z4L5 | protein_coding | tolerated(0.56) | benign(0) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
TTC21B | SNV | Missense_Mutation | | c.1016N>T | p.Arg339Ile | p.R339I | Q7Z4L5 | protein_coding | deleterious(0) | benign(0.193) | TCGA-AN-A0AK-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
TTC21B | SNV | Missense_Mutation | | c.1993N>A | p.Leu665Ile | p.L665I | Q7Z4L5 | protein_coding | tolerated(0.09) | benign(0.085) | TCGA-BH-A0EE-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | docetaxel | SD |
TTC21B | SNV | Missense_Mutation | | c.781N>T | p.Gly261Trp | p.G261W | Q7Z4L5 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-BH-A203-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
TTC21B | insertion | Frame_Shift_Ins | novel | c.873_874insT | p.Thr292TyrfsTer11 | p.T292Yfs*11 | Q7Z4L5 | protein_coding | | | TCGA-E2-A15C-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | arimidex | SD |
TTC21B | SNV | Missense_Mutation | | c.1834N>T | p.Asp612Tyr | p.D612Y | Q7Z4L5 | protein_coding | deleterious(0.02) | possibly_damaging(0.526) | TCGA-C5-A1MJ-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
TTC21B | SNV | Missense_Mutation | novel | c.2215G>A | p.Glu739Lys | p.E739K | Q7Z4L5 | protein_coding | deleterious(0) | possibly_damaging(0.755) | TCGA-C5-A8XK-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | SD |